Kanawha Capital Management LLC Abb Vie Inc. Transaction History

Kanawha Capital Management LLC

$1.29 Billion
Q3 2024

A detailed history of Kanawha Capital Management LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Kanawha Capital Management LLC holds 142,432 shares of ABBV stock, worth $25.5 Million. This represents 2.17% of its overall portfolio holdings.

Number of Shares

142,432

Previous 148,846 4.31%

Holding current value

$25.5 Million

Previous $25.5 Million 10.17%

% of portfolio

2.17%

Previous 2.1%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	SELL	$163.84 - $199.33 $1.05 Million - $1.28 Million	-6,414 Reduced 4.31%	142,432 $28.1 Million
Q2 2024 Jul 25, 2024	BUY	$154.79 - $180.76 $1.04 Million - $1.22 Million	6,724 Added 4.73%	148,846 $25.5 Million
Q1 2024 Apr 29, 2024	BUY	$159.82 - $182.1 $67,444 - $76,846	422 Added 0.3%	142,122 $25.9 Million
Q4 2023 Jan 29, 2024	SELL	$137.6 - $154.97 $1.23 Million - $1.39 Million	-8,939 Reduced 5.93%	141,700 $22 Million
Q3 2023 Oct 26, 2023	SELL	$133.59 - $154.65 $159,239 - $184,342	-1,192 Reduced 0.79%	150,639 $22.5 Million
Q2 2023 Jul 28, 2023	SELL	$132.51 - $164.9 $39,753 - $49,470	-300 Reduced 0.2%	151,831 $20.5 Million
Q1 2023 May 08, 2023	BUY	$144.61 - $166.54 $41,936 - $48,296	290 Added 0.19%	152,131 $24.2 Million
Q4 2022 Feb 01, 2023	SELL	$138.31 - $165.87 $59,058 - $70,826	-427 Reduced 0.28%	151,841 $24.5 Million
Q3 2022 Oct 31, 2022	SELL	$134.21 - $153.93 $212,051 - $243,209	-1,580 Reduced 1.03%	152,268 $20.4 Million
Q2 2022 Jul 27, 2022	SELL	$137.62 - $174.96 $237,394 - $301,806	-1,725 Reduced 1.11%	153,848 $23.6 Million
Q1 2022 Apr 26, 2022	BUY	$131.98 - $163.75 $32,599 - $40,446	247 Added 0.16%	155,573 $25.2 Million
Q4 2021 Jan 31, 2022	SELL	$107.43 - $135.93 $344,635 - $436,063	-3,208 Reduced 2.02%	155,326 $21 Million
Q3 2021 Oct 28, 2021	SELL	$106.4 - $120.78 $60,754 - $68,965	-571 Reduced 0.36%	158,534 $17.1 Million
Q2 2021 Jul 22, 2021	SELL	$105.21 - $117.21 $28,617 - $31,881	-272 Reduced 0.17%	159,105 $17.9 Million
Q1 2021 Apr 26, 2021	SELL	$102.3 - $112.62 $249,714 - $274,905	-2,441 Reduced 1.51%	159,377 $17.2 Million
Q4 2020 Feb 01, 2021	BUY	$80.49 - $108.67 $77,270 - $104,323	960 Added 0.6%	161,818 $17.3 Million
Q3 2020 Oct 29, 2020	BUY	$85.91 - $100.83 $10,395 - $12,200	121 Added 0.08%	160,858 $14.1 Million
Q2 2020 Aug 04, 2020	BUY	$73.37 - $98.18 $72,196 - $96,609	984 Added 0.62%	160,737 $15.8 Million
Q1 2020 May 04, 2020	BUY	$64.5 - $97.79 $127,323 - $193,037	1,974 Added 1.25%	159,753 $12.2 Million
Q4 2019 Jan 31, 2020	BUY	$72.13 - $90.25 $692,231 - $866,129	9,597 Added 6.48%	157,779 $14 Million
Q3 2019 Nov 01, 2019	BUY	$62.98 - $75.72 $53,910 - $64,816	856 Added 0.58%	148,182 $11.2 Million
Q2 2019 Jul 30, 2019	SELL	$65.7 - $83.98 $253,667 - $324,246	-3,861 Reduced 2.55%	147,326 $10.7 Million
Q1 2019 Apr 23, 2019	SELL	$77.14 - $90.79 $268,910 - $316,493	-3,486 Reduced 2.25%	151,187 $12.2 Million
Q4 2018 Jan 23, 2019	SELL	$77.85 - $96.01 $105,953 - $130,669	-1,361 Reduced 0.87%	154,673 $14.3 Million
Q3 2018 Oct 25, 2018	SELL	$88.91 - $98.84 $127,319 - $141,538	-1,432 Reduced 0.91%	156,034 $14.8 Million
Q2 2018 Jul 27, 2018	SELL	$89.78 - $106.23 $97,411 - $115,259	-1,085 Reduced 0.68%	157,466 $14.6 Million
Q1 2018 Apr 19, 2018	SELL	$92.01 - $123.21 $307,681 - $412,014	-3,344 Reduced 2.07%	158,551 $15 Million
Q4 2017 Jan 26, 2018	SELL	$89.56 - $98.21 $194,076 - $212,821	-2,167 Reduced 1.32%	161,895 $15.7 Million
Q3 2017 Oct 26, 2017	BUY	$69.85 - $89.22 $11.5 Million - $14.6 Million	164,062	164,062 $14.6 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kanawha Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kanawha Capital Management LLC with notifications on news.

Account

Kanawha Capital Management LLC Abb Vie Inc. Transaction History